Follow-up results for Phase III trial of Gattex provide promise
This article was originally published in Scrip
Executive Summary
Follow-up results of a Phase III trial of NPS Pharmaceuticals's Gattex (teduglutide) offer hope for short bowel syndrome patients, suggesting that the orphan drug provides several benefits including improved absolute intestinal absorption and decreased electrolyte loss.